Plain-English translation of NCT07109219 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called AZD4512 for young people with acute lymphoblastic leukemia (a type of blood cancer) that has either come back after treatment or stopped responding to previous therapies. The study has two parts: first, researchers will test different doses to find the safest and most effective amount, and then they will test the chosen dose in a larger group of patients to confirm it works well.
People with acute lymphoblastic leukemia that comes back or resists standard treatments have very limited options and poor outcomes. This trial exists to see whether this new medication can help these patients by targeting the cancer cells in a different way than treatments already available.
You likely qualify if…
You likely don't qualify if…
You would receive AZD4512 as either a monotherapy or potentially combined with other cancer medications, depending on which part of the study you join. The first part involves testing gradually increasing doses to find the safest level; the second part involves receiving an optimized dose to confirm safety and effectiveness. You would attend regular visits at a clinical research center for check-ups, blood tests, and imaging scans to monitor how you're responding to the treatment.
AI-generated summary from trial data · Jul 16, 2026 · Not medical advice
United States